ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2025
Prognostic utility of pre-biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence.
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic utility of pre-biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBiologics have been shown to substantially reduce the risk of severe asthma exacerbations (SAEs) among children with moderate or severe asthma; however, not all eligible patients who initiate biologic treatment experience a reduced risk of SAEs.
methodsUsing a longitudinal study design, we analyzed data from 122 children with moderate/severe asthma treated with a biologic by pediatric subspecialists between December 2019 and December 2024. We used logistic and Cox proportional hazards models to identify and quantify the prognostic utility of clinical correlates of increased SAE risk among children with moderate or severe asthma prior to biologic treatment initiation.
resultsBiologic agents (dupilumab, omalizumab, and mepolizumab) had differential effects on the risk of SAE depending on a child's sex (p = .024), age of treatment initiation (p = .010), lung function (% FEF
conclusionBeyond biologic treatment eligibility, using routinely collected clinical parameters to stratify pre-treatment SAE risk could improve prognostic accuracy and aid clinicians in tailoring therapy based on a patient's individual risk factors and likelihood of responding to a specific agent to maximize treatment effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.